SERUM OSTEOPROTEGERIN FOR EARLY IDENTIFICATION OF CAD IN TYPE 2 DM PATIENTS

Authors

  • Jayapriya S, Ashok G, Divya Lakshmi V and Abishkauf Jenish Beautlin GARG Author

Keywords:

Osteoprotegerin (OPG)

Abstract

Background:

Osteoprotegerin (OPG) is a well-known protein, it can reduce the osteoclast production and it also be used to identify people with CAD. The aim of this study was to investigate OPG levels, CIMT, and CAC measures in diabetic participants, as well as examine the link between blood OPG levels and early atherosclerosis such as CIMT, CAC, and GLS in patients with type 2 DM.

Method:

The study included 160 type 2 DM patients. All study were investigated GLS and venous blood specimens were collected to determine OPG. Serum OPG levels was determined using an ELISA. FPG, PPBS, and HbA1c values were assessed. CIMT were measured with B-mode ultrasonography, CAC were measured with CT.

Results:

Downloads

Download data is not yet available.

Downloads

Published

2025-06-07

Issue

Vol. 2 No. 3 (2023): IJER: Engineering Research

Section

Articles

License

Copyright (c) 2023 International Journal of Engineering Research

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

IJMR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.

How to Cite

SERUM OSTEOPROTEGERIN FOR EARLY IDENTIFICATION OF CAD IN TYPE 2 DM PATIENTS. (2025). International Journal of Engineering Research, 2(3), 20-50. https://ijeres.org/index.php/ijer/article/view/10